The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health

<p>Abstract</p> <p>Background</p> <p>Metabolic Syndrome, or Syndrome X, is characterized by a set of metabolic and lipid imbalances that greatly increases the risk of developing diabetes and cardiovascular disease. The syndrome is highly prevalent in the United States and worldwide, and treatments are in high demand. ProAlgaZyme, a novel and proprietary freshwater algae infusion in purified water, has been the subject of several animal studies and has demonstrated low toxicity even with chronic administration at elevated doses. The infusion has been used historically for the treatment of several inflammatory and immune disorders in humans and is considered well-tolerated. Here, the infusion is evaluated for its effects on the cardiovascular risk factors present in metabolic syndrome in a randomized double-blind placebo-controlled study involving 60 overweight and obese persons, ages 25–60. All participants received four daily oral doses (1 fl oz) of ProAlgaZyme (N = 22) or water placebo (N = 30) for a total of 10 weeks, and were encouraged to maintain their normal levels of physical activity. Blood sampling and anthropometric measurements were taken at the beginning of the study period and after 4, 8 and 10 weeks of treatment. Eight participants did not complete the study.</p> <p>Results</p> <p>ProAlgaZyme brought about statistically significant (p < 0.001) reductions in the following: weight, body fat, total cholesterol, LDL-cholesterol, triglycerides, C-reactive protein and fasting blood glucose levels, accompanied by a significant (p < 0.001) increase in HDL-cholesterol levels over the 10-week study period. The infusion was well-tolerated and no side effects were noted.</p> <p>Conclusion</p> <p>ProAlgaZyme (4 fl oz daily) consumption resulted in significant reductions in weight and blood glucose levels, while significantly improving serum lipid profiles and reducing markers of inflammation, thus improving cardiovascular risk factors in overweight and obese subjects over a course of 10 weeks with an absence of adverse side effects.</p> <p>Trial Registration</p> <p>US ClinicalTrials.gov NCT00489333</p

The Government-led initiative for liquified petroleum gas (LPG) scale-up in Cameroon: programme development and initial evaluation

In 2016, the government of Cameroon, a central African country heavily reliant on wood fuel for cooking, published a Masterplan for increasing primary use of LPG from 20% to 58% of households by 2035. Developed via a multi-sectoral committee with support from the Global LPG Partnership, the plan envisages a 400 million Euro investment program to 2030, focused on increasing LPG cylinder numbers, key infrastructure, and enhanced regulation. This case study describes the Masterplan process and investment proposals and draws on community studies and stakeholder interviews to identify factors likely to impact on the planned expansion of LPG use

The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health-3

<p><b>Copyright information:</b></p><p>Taken from "The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health"</p><p>http://www.lipidworld.com/content/6/1/20</p><p>Lipids in Health and Disease 2007;6():20-20.</p><p>Published online 5 Sep 2007</p><p>PMCID:PMC2034560.</p><p></p>andard error of the mean))

The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health-4

<p><b>Copyright information:</b></p><p>Taken from "The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health"</p><p>http://www.lipidworld.com/content/6/1/20</p><p>Lipids in Health and Disease 2007;6():20-20.</p><p>Published online 5 Sep 2007</p><p>PMCID:PMC2034560.</p><p></p>andard error of the mean))

The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health-0

<p><b>Copyright information:</b></p><p>Taken from "The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health"</p><p>http://www.lipidworld.com/content/6/1/20</p><p>Lipids in Health and Disease 2007;6():20-20.</p><p>Published online 5 Sep 2007</p><p>PMCID:PMC2034560.</p><p></p>andard error of the mean))

The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health-1

<p><b>Copyright information:</b></p><p>Taken from "The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health"</p><p>http://www.lipidworld.com/content/6/1/20</p><p>Lipids in Health and Disease 2007;6():20-20.</p><p>Published online 5 Sep 2007</p><p>PMCID:PMC2034560.</p><p></p>andard error of the mean))